BCCHR Main Site

BRAvE Initiative

The BRAvE InitiativePublications

Publications

Select publications from the BRAvE Initiative team.

Journals

  1. Herzenberg G, Bhat TA, Csizmok V, Shen Y, Reid GSD, Maxwell CA, Lange P, Renouf D, Bush JW, Gowdy C, Piper HG, Marra MA, Laskin J, Rassekh SR, Lim CJ, Deyell RJ. mTOR Inhibition in the Management of Recurrent Metastatic Solid Pseudopapillary Tumor of the Pancreas. Pediatr Blood Cancer. 2026 Feb;73(2):e70083. doi: 10.1002/1545-5017.70083. Epub 2025 Dec 30. PMID: 41472396.
  2. Barnabas GD, Bhat TA, Goebeler V, Leclair P, Azzam N, Melong N, Anderson C, Gom A, An S, Ergin EK, Shen Y, Mungall AJ, Mungall KL, Maxwell CA, Reid GSD, Hirst M, Jones S, Chan JA, Senger DL, Berman JN, Parker SJ, Bush JW, Strahlendorf C, Deyell RJ, Lim CJ, Lange PF. Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe. EMBO Mol Med. 2025 Apr 1. doi.org/10.1038/s44321-025-00212-8
  3. Lorentzian AC, Rever J, Ergin EK, Guo M, Akella NM, Rolf N, Lim CJ, Reid GSD, Maxwell CA, Lange PF. Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. Nat Commun. 2023 Nov 21;14(1):7161. doi: 10.1038/s41467-023-42701-9. PMID: 37989729; PMCID: PMC10663560.
  4. Barnabas GD, Goebeler V, Tsui J, Bush JW, Lange PF. ASAP─Automated Sonication-Free Acid-Assisted Proteomes─from Cells and FFPE Tissues. Anal Chem. 2023 Feb 14;95(6):3291-3299. doi: 10.1021/acs.analchem.2c04264. Epub 2023 Feb 1. PMID: 36724070; PMCID: PMC9933881.
  5. *Rolf N, Liu LYT, Tsang A, Lange PF, Lim CJ, Maxwell CA, Vercauteren SM, Reid GSD. A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts. Cytometry A. 2022 Jan;101(1):57-71. doi: 10.1002/cyto.a.24473. Epub 2021 Jun 25. PMID: 34128309; PMCID: PMC9292200.
    *Featured as one of two “must-read” articles in the monthly roundup of the European Journal of Immunology. Dissecting phenotypic subpopulation complexity in childhood leukemia for PDX-based precision medicine approaches. Eur. J. Immunol. (2021) 51(9):2114, DOI: 10.1002/eji.202170094.
  6. Uzozie AC, Ergin EK, Rolf N, Tsui J, Lorentzian A, Weng SSH, Nierves L, Smith TG, Lim CJ, Maxwell CA, Reid GSD, Lange PF. PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways. J Exp Clin Cancer Res. 2021 Mar 15; 40(1):96. doi: 10.1186/s13046-021-01835-8. PMID: 33722259; PMCID: PMC7958471.
  7. Lorentzian A, Biegel JA, Ostrow DG, Rolf N, Liu CC, Rassekh SR, Deyell RJ, Triche T, Schultz KR, Rozmus J, Reid GSD, Lim CJ, Lange PF, Maxwell CA. Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. JNCI Cancer Spectr. 2018 Oct;2(4):pky079. doi: 10.1093/jncics/pky079. Epub 2019 Jan 25. PMID: 30976750; PMCID: PMC6447067.


Meeting Abstracts

  1. Lim CJ 1, Deyell R 2, Telford S 3, Azzam N, Berman J, Senger DL, on behalf of PPMP-ACCESS. A national pediatric preclinical modelling program to advance precision oncology for childhood cancers in Canada. ACCESS 3rd Annual Meeting, Toronto, ON. Mar 10-11, 2026. (Impact Presentation – Oral Symposium). Presenters: 1 lead, 2 clinician, 3 PWLE.
  2. Li VL, Hung W-H, Leclair P, Roskelley CD, McNagny KM, Bush JW, Lim CJ. Patient-derived organoids (PDOs) to model nephroblastoma (Wilms tumour). ACCESS 3rd Annual Meeting, Toronto, ON. Mar 10-11, 2026. (Poster #47)
  3. Herzenberg G, Bhat TA, Csizmok V, Shen Y, Reid GSD, Maxwell CA, Lange P, Renouf D, Bush JW, Gowdy C, Piper HG, Marra MA, Laskin J, Rassekh SR, Lim CJ, Deyell RJ. mTOR inhibition in the management of recurrent metastatic solid pseudopapillary tumor of the pancreas. Canadian Cancer Research Conference, Calgary, AB. Nov03, 2025 (#16: Speed Talk and Poster).
  4. Ferguson KM, Barnabas GD, Bhat TA, Goebeler V, Leclair P, Conrerro A, Ergin EK, Bush J, Lim CJ, Lange PF. Proteomics: complementary insights in precision oncology. Canadian Cancer Research Conference, Calgary, AB. Nov02-04, 2025 (Short Talk-Concurrent D1).
  5. Azzam N, Senger DL, Lim CJ, Berman J, on behalf of PPMP-ACCESS. A national pediatric preclinical modelling program to advance precision oncology for childhood cancers in Canada. Canadian Cancer Research Conference, Calgary, AB. Nov02-04, 2025 (Short Talk-Concurrent A3).
  6. Rolf N, Liu LYT, Leclair P, Atre T, Vercauteren S, Lim CJ, Reid GSD. High-dimensional single-cell analysis of clinical-grade flow cytometry explains the unpredictable complex shifts of patient-specific immunophenotypes during B-ALL relapse. Blood 144 (Supplement 1), 5928-5928 (2024).
  7. Barnabas GD, Bhat TA, Goebeler V, Leclair P, Maxwell CA, Reid GS, Senger DL, Chan JA, Azzam N, Melong N, Berman JN, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF. Canada’s path towards proteome guided therapies and advanced molecular pathology in pediatric precision oncology. Cancer Research 84 (17_Supplement), PR003-PR003 (2024).
  8. Barnabas GD, Bhat TA, Goebeler V, Leclair P, Azzam N, Melong N, Berman JN, Chan JA, Senger DL, Parker S, Maxwell CA, Reid GS, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF. Prioritizing treatment targets for an adolescent with metastatic processive malignancy using proteomics and personalized xenograft models within an actionable timeframe. Cancer Research 84 (6_Supplement), 937-937 (2024).
  9. Bhat TA, Barnabas GD, Goebeler V, Leclair P, Maxwell CA, Reid GS, Bush J, Parker S, Senger DL, Berman JN, Strahlendorf C, Deyell R, Lange PF, Lim CJ, PROFYLE program. Proteomics and patient-derived xenograft models identify treatment for a rare pediatric malignancy in a clinically actionable time frame. Precision Child Health: From Technology to Translation, Toronto, ON. Sep30-Oct02, 2024 (Poster).
  10. Bhat TA, Barnabas GD, Leclair P, Goebeler V, Maxwell CA, Deyell R, Strahlendorf C, Reid GS, Bush J, Parker S, Azzam N, Melong N, Berman JN, Senger DL, Lange PF, CJ Lim, on behalf of the PROFYLE program. Pre-clinical modeling of precision oncology for an adolescent with SETTLE tumour. Canadian Cancer Research Conference, Halifax, NS. Nov11-14, 2023 (Poster).
  11. Zhu Z, Bhat TA, An S, Lim CJ, Bush JW. Development of Rhabdoid Tumor Patient-Derived Xenografts Using the Chicken Chorioallantoic Membrane System. Society for Pediatric Pathology Fall Meeting, Portland, Oregon, USA. October 6-8, 2023. Platform presentation and recipient of Harry B. Neustein Award.
  12. Bhat TA, Barnabas GD, Goebeler V, Leclair P, Maxwell CA, Deyell R, Strahlendorf C, Bush J, Reid GS, Lange PF, Lim CJ, on behalf of the PROFYLE program. Evaluating Targeted Drug Therapies for Pediatric Tumours Using the Chick Chorioallantoic Membrane (CAM) Xenograft Model. JCA-AACR Precision Cancer Medicine International Conference, Kyoto, Japan. Jun28-30, 2023 (Poster).
  13. Rolf N, Liu LYT, Leclair P, Lorentzian A, Lange PF, Maxwell CA, Vercauteren SM, Lim CJ, Reid GSD.Investigating the role of phenotypic complexity during clinical disease progression using paired patient-derived xenografts of childhood ALL. 3rd Translational Research Conference: Acute Lymphoblastic Leukemia of the European School of Hematology (ESH), Berlin, Germany, May 19-21, 2023.
  14. Barnabas GD, Bhat TA, Goebeler V, Maxwell CA, Reid GS, Senger D, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF, and on behalf of the PROFYLE program. Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. 9th TFRI Scientific Meeting, Vancouver. Nov, 2022 (Poster)
  15. Bhat TA, Barnabas GD, Goebeler V, Leclair P, Maxwell CA, Deyell R, Strahlendorf C, Bush J, Reid GS, Lange PF, Lim CJ, on behalf of the PROFYLE program. Evaluating Targeted Drug Therapies for Pediatric Tumours Using the Chick Chorioallantoic Membrane (CAM) Xenograft Model. 9th TFRI Scientific Meeting, Vancouver. Nov, 2022 (Poster & Rapid-Fire Talk)
  16. Barnabas GD, Bhat TA, Goebeler V, Maxwell CA, Reid GS, Senger D, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF, and on behalf of the PROFYLE program. Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. Zero Childhood Cancer (ZERO) National Symposium. Oct, 2022 (Poster & Rapid-Fire Talk)
  17. Rolf N, Liu LYT, Tsang A, Vercauteren SM, Reid GSD. Stability of leukemia immunophenotypes through disease progression. BCCHR Childhood Diseases Theme Symposium. Oct, 2022 (Poster)
  18. Lorentzian A, Guo M, Ergin EK, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Proteogenomic analysis identifies the persistence of targetable genomes and proteomes through disease evolution in pediatric acute lymphoblastic leukemia. International Society of Pediatric Oncology (SIOP) Conference Barcelona, Spain. Sept, 2022 (Poster & Discussion Panel)
  19. Lorentzian A, Guo M, Ergin EK, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of targetable lesions and proteomes through disease evolution in pediatric acute lymphoblastic leukemia. Canadian National Proteomics Network (CNPN) Conference Montreal, QC. May, 2022 (Oral Presentation)
  20. Leclair P, Lorentzian A, Rolf N, Goebeler V, Lange P, Maxwell C, Reid G, and Lim CJ. A Pre-Clinical Platform to Assess Efficacy for Precision Molecular Targeted Therapies in Pediatric Acute Lymphoblastic Leukemia. SIOP 2021 Virt Congress. Oct, 2021 (Poster)
  21. Rolf N, Liu LYT, Lorentzian A, Leclair P, Goebeler V, Lange PF, Lim CJ, Maxwell CA, Vercauteren SM, Reid GSD. Longitudinal assessment of phenotypic heterogeneity and subpopulation trajectories in B-ALL disease progression samples, 53rd Congress of the International Society of Pediatric Oncology (SIOP, Virtual). Pediatric Blood and Cancer (2021), 68: S166, #1443, Oct 2021 (Poster).
  22. Lorentzian A, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of proteomes, targetable lesions, and therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. International Society of Pediatric Oncology (SIOP) Conference (Virtual) Sept, 2021 (Poster).
  23. Uzozie A, Ergin E, Lorentzian A, Rolf N, Lim CJ, Reid G, Maxwell CA, and Lange PF. Patient-derived xenograft models recapitulate the proteome and functional capacity of primary pediatric acute lymphoblastic leukemia but divert in select pathways. International Society of Pediatric Oncology (SIOP) Conference (Virtual) Sept, 2021 (Poster).
  24. Lorentzian A, Rolf N, Leclair P, Akella N, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of targetable lesions, proteome state, and predicted drug sensitivity through disease progression in pediatric acute lymphoblastic leukemia. Canadian National Proteomics Network (CNPN) Conference (Virtual) May, 2021. (Oral Presentation).
  25. Rolf N, Tsang A, Liu LYT, Lorentzian A, Leclair P, Patterson A, Lange PF, Maxwell CA, Lim CJ, Klein-Geltink R, Vercauteren SM, Reid GSD. MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initating Potential, 63rd Annual Meeting of the American Society of Hematology (ASH, Virtual). Blood 136, S1: 12-13. Dec, 2020 (Poster). 
  26. Rolf N, Liu LYT, Tsang A, Vercauteren SM, Reid GSD. A cross-standardized analytical platform to permit comparison of immunophenotypic subpopulations between acute lymphoblastic leukemia patients and their patient-derived xenografts, Annual Meeting of the International Clinical Cytometry Society (ICCS, Virtual). Sept, 2020 (Poster; *1 out 5 Panelists selected for Virtual Poster Walk)
  27. Uzozie A, Tsui J, Maxwell CA, Lim CJ, Reid G, and Lange PF. Integrated proteome, phospho-proteome and N terminome characterization of pediatric patient and matched engrafted leukemia. Canadian National Proteomics Network (CNPN) Conference, Montreal, QC. May, 2019 (Oral Presentation).
  28. Lorentzian A, Rolf N, Reid GSD, Lim CJ, Lange PF and Maxwell CA. Accounting for the Unique Molecular Landscape of Pediatric Malignancies Improves Target-Agent Pair Identification for Pediatric Precision Oncology. American Society of Hematology (ASH), San Diego, USA. Dec, 2018. (Poster)

News

The BRAvE Initiative in the news.

News